The company had posted a net profit of Rs 321.57 crore for the corresponding period of the previous fiscal hit by one-time deferred tax adjustment.
"Net profit for Q3 FY19 was at Rs 1,242 crore with resulting net profit margin at 16.2 per cent. Net profit for third quarter last year was adversely impacted by one-time deferred tax adjustment of Rs 513 crore related to changes in US tax rates. Adjusted for this, net profit growth for Q3 FY19 was 49 per cent year-on-year," Sun Pharmaceutical Industries said in a filing to BSE.
Consolidated revenue from operations of the company stood at Rs 7,740.19 crore for the quarter under consideration as against Rs 6,653.23 crore for the same period a year ago.
Commenting on the results, Sun Pharma MD Dilip Shanghvi said: "Our focus on execution is reflected in the Q3 performance."
The company remains committed towards executing its global specialty strategy, strengthening core operations and enhancing its overall efficiencies, he added.
"The Ilumya launch in US has been well received by doctors. We recently commercialised Xelpros in the US and are preparing to launch Cequa in the coming months," Shanghvi said.
Sales in the US were at USD 362 million for the quarter under consideration, a growth of 10 per cent over same period last year and accounted for 34 per cent of total sales, it added.
"Our sales in emerging markets were at USD 203 million for Q3; up 7 per cent over same quarter last year and accounted for 19 per cent of total sales," Sun Pharma said.
Formulation sales in Rest of World (ROW) markets excluding US and Emerging Markets were at USD 125 million in the third quarter of 2018-19, a growth of 4 per cent over the year-ago quarter and accounting for approximately 12 per cent of revenues, it added.
Shares of Sun Pharmaceutical Industries closed at Rs 436.75 on BSE, up 2 per cent from the previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)